ArticleDalton transactions (Cambridge, England : 2003)2016
Synthesis and anticancer activity of carbosilane metallodendrimers based on arene ruthenium(ii) complexes.
Article in Dalton transactions (Cambridge, England : 2003), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 74 citations in OpenAlex.
- The repertoire of iron superoxide dismutases fromJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Zinc(II) Iminopyridine Complexes as Antibacterial Agents: A Structure-to-Activity Study.International journal of molecular sciences · 2024Article
- A Ru(II)-Strained Complex with 2,9-Diphenyl-1,10-phenanthroline Ligand Induces Selective Photoactivatable Chemotherapeutic Activity on Human Alveolar Carcinoma Cells via Apoptosis.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Development of Responsive Nanoparticles for Cancer Therapy.International journal of molecular sciences · 2023Article
- A Glimpse into Dendrimers Integration in Cancer Imaging and Theranostics.International journal of molecular sciences · 2023Review
- Alteration of the HIF-1α/VEGF Signaling Pathway and Disruption of the Cell Cycle by Second Generation Carbosilan Dendrimers.Biomacromolecules · 2022Article
- Amphiphilic Triazine-Phosphorus Metallodendrons Possessing Anti-Cancer Stem Cell Activity.Pharmaceutics · 2022Article
- Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2021Article
- Insight on the Structure-to-Activity of Carbosilane Metallodendrimers in the Fight againstAntibiotics (Basel, Switzerland) · 2021Article
- Copper (II) Metallodendrimers Combined with Pro-Apoptotic siRNAs as a Promising Strategy Against Breast Cancer Cells.Pharmaceutics · 2020Article
- Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells.International journal of molecular sciences · 2020Article
- Ruthenium Complex Induce Cell Death in G-415 Gallbladder Cancer Cells.Journal of gastrointestinal cancer · 2020Article
- Recent advances in metallopolymer-based drug delivery systems.RSC advances · 2019Review
- Article
- Synthesis and Characterization of FITC Labelled Ruthenium Dendrimer as a Prospective Anticancer Drug.Biomolecules · 2019Article
- Synthesis and in vitro activity of new biguanide-containing dendrimers on pathogenic isolates of Acanthamoeba polyphaga and Acanthamoeba griffini.Parasitology research · 2019Article
- Poly(alkylidenimine) Dendrimers Functionalized with the Organometallic Moiety [Ru(η⁵-C₅H₅)(PPh₃)₂]⁺ as Promising Drugs AgainstMolecules (Basel, Switzerland) · 2018Article
- Metal complexes in cancer therapy - an update from drug design perspective.Drug design, development and therapy · 2017Review
- Antimetastatic activity of novel ruthenium (III) pyridine complexes.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
A series of new organometallic carbosilane dendrimers (first and second generation) and the corresponding non-dendritic mononuclear based on ruthenium arene fragments are described. The metallodendrimers were prepared by reactions of the precursor [Ru(η(6)-p-cymene)Cl2]2 with carbosilane dendrimers functionalized with N-donor monodentate ligands such as NH2- and pyridine, or with N,O-, N,N-chelating imine ligands. While the dendrimer precursors are insoluble in DMSO or water, novel metallodendrimers are soluble in DMSO and some of them are even highly soluble in water. The molecular structure of the "Ru-NH2" mononuclear compound (zero generation) was determined by single-crystal X-ray crystallography. The cytotoxicity activity of these dendritic structures was evaluated in several human cancer cell lines and compared with that of the corresponding mononuclear ruthenium complexes. Most compounds display significant cytotoxic activities in the low micromolar range with the first generation ruthenium dendrimers being the most active compounds. The cell death type for selected compounds has been studied as well as their reactivity towards relevant biomolecules such as DNA, Human Serum Albumin (HSA) and Cathepsin-B. All the data point to a mode of action different from that of cisplatin for most complexes. First generation ruthenium dendrimers inhibit Cathepsin-B, which may suggest potential antimetastatic properties of these compounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.